Skip to main content

Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years

The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.